Stockscreener 앱 받기
4.41
1.78%
-0.08
시장 영업 전:
4.49
0.08
+1.81%
전일 마감가:
$4.49
열려 있는:
$4.53
하루 거래량:
84,123
Relative Volume:
0.29
시가총액:
$41.37M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.50%
1개월 성능:
+4.01%
6개월 성능:
-83.11%
1년 성능:
+0.00%
1일 변동 폭
$4.38
$4.57
1주일 범위
$4.05
$4.71
52주 변동 폭
$3.74
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
명칭
Tvardi Therapeutics Inc
전화
(713) 489-8654
주소
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
TVRD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
4.41 | 42.12M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-10-14 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-10-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | 개시 | Raymond James | Outperform |
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | Piper Sandler | Overweight |
| 2025-05-21 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 개시 | BTIG Research | Buy |
| 2024-06-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-03-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 재개 | Canaccord Genuity | Buy |
| 2021-08-03 | 개시 | JP Morgan | Neutral |
| 2020-04-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-29 | 재확인 | Laidlaw | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2019-01-15 | 개시 | BofA/Merrill | Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Jefferies | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-12 | 재개 | H.C. Wainwright | Buy |
| 2018-02-12 | 업그레이드 | Janney | Neutral → Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
모두보기
Tvardi Therapeutics Inc 주식(TVRD)의 최신 뉴스
What analysts say about Tvardi Therapeutics Inc stockCash Flow Trends & Affordable Portfolio Growth - earlytimes.in
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials - MSN
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - GlobeNewswire
Tvardi Therapeutics (TVRD) Price Target Decreased by 24.64% to 15.15 - MSN
How Low Can Tvardi Therapeutics Stock Really Go? - Trefis
Tvardi Therapeutics (TVRD) Stock Analysis Report | Financials & Insights - Benzinga
Will Tvardi Therapeutics Inc. (69C) stock outperform value peersJuly 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - Newser
Can Tvardi Therapeutics Inc. stock sustain institutional interestTrade Exit Summary & Detailed Earnings Play Alerts - Newser
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - Barchart.com
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Tvardi Therapeutics - Menafn.com
Is Tvardi Therapeutics Inc. (69C) stock trading at attractive multiplesChart Signals & Fast Exit and Entry Trade Guides - Newser
Why Tvardi Therapeutics Inc. (69C) stock could outperform next yearWeekly Profit Analysis & Technical Pattern Recognition Alerts - Newser
With Tvardi Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Will Tvardi Therapeutics Inc. (69C) stock see insider accumulationJuly 2025 Big Picture & Low Drawdown Trading Techniques - Newser
How big funds are accumulating Tvardi Therapeutics Inc. (69C) stockJuly 2025 Trends & Free Real-Time Market Sentiment Alerts - Newser
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Tvardi Therapeutics - The National Law Review
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - GlobeNewswire
Why retail investors favor Tvardi Therapeutics Inc. stockWeekly Trade Report & Capital Protection Trading Alerts - moha.gov.vn
Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Upgraded by Wall Street Zen - Defense World
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario - TipRanks
Will Tvardi Therapeutics Inc. (69C) stock enhance shareholder value2025 Momentum Check & Smart Money Movement Tracker - newser.com
Can Tvardi Therapeutics Stock Recover If Markets Fall? - Trefis
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
How Tvardi Therapeutics Inc. (69C) stock reacts to stronger dollarPortfolio Profit Report & AI Forecast for Swing Trade Picks - newser.com
Is Tvardi Therapeutics Inc. stock ready for a breakoutPortfolio Performance Summary & Capital Protection Trading Alerts - newser.com
Will Tvardi Therapeutics Inc. benefit from macro trendsJuly 2025 Weekly Recap & Weekly Breakout Stock Alerts - newser.com
Can Tvardi Therapeutics Inc. (69C) stock expand revenue streamsJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
What valuation ratios show for Tvardi Therapeutics Inc. (69C) stockJuly 2025 Big Picture & Trade Opportunity Analysis - newser.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Tvardi Therapeutics, Inc. (TVRD) And Encourages Shareholders to Connect - ACCESS Newswire
Can Tvardi Therapeutics Inc. (69C) stock deliver double digit returnsRisk Management & Weekly Chart Analysis and Trade Guides - newser.com
How to interpret RSI for Tvardi Therapeutics Inc. stockJuly 2025 Retail & Daily Chart Pattern Signals - newser.com
Tvardi Therapeutics, Inc. Updates on Clinical Trials and Pipeline Progress - TradingView
How Tvardi Therapeutics Inc. stock reacts to global recession fearsEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com
Tvardi Therapeutics Inc (TVRD) 재무 분석
Tvardi Therapeutics Inc (TVRD)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):